Chordoma: The nonsarcoma primary bone tumor

被引:279
作者
Chugh, Rashmi
Tawbi, Hussein
Lucas, David R.
Biermann, J. Sybil
Schuetze, Scott M.
Baker, Laurence H.
机构
[1] Univ Michigan, Div Hematol Oncol, Dept Internal Med, Ann Arbor, MI 48106 USA
[2] Univ Michigan, Dept Pathol, Ann Arbor, MI 48106 USA
[3] Univ Michigan, Dept Orthoped Surg, Ann Arbor, MI 48106 USA
[4] Univ Pittsburgh, Pittsburgh Canc Inst, Div Hematol Oncol, Dept Med, Pittsburgh, PA USA
关键词
chordoma; bone tumors; proton radiation;
D O I
10.1634/theoncologist.12-11-1344
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chordomas are rare, slowly growing, locally aggressive neoplasms of bone that arise from embryonic remnants of the notochord. These tumors typically occur in the axial skeleton and have a proclivity for the spheno-occipital region of the skull base and sacral regions. In adults, 50% of chordomas involve the sacrococcygeal region, 35% occur at the base of the skull near the spheno-occipital area, and 15% are found in the vertebral column. Craniocervical chordomas most often involve the dorsum sella, clivus, and nasopharynx. Chordomas are divided into conventional, chondroid, and dedifferentiated types. Conventional chordomas are the most common. They are characterized by the absence of cartilaginous or additional mesenchymal components. Chondroid chordomas contain both chordomatous and chondromatous features, and have a predilection for the spheno-occipital region of the skull base. This variant accounts for 5%-15% of all chordomas and up to 33% of cranial chordomas. Dedifferentiation or sarcomatous transformation occurs in 2%-8% of chordomas. This can develop at the onset of the disease or later. Aggressive initial therapy improves overall outcome. Patients who relapse locally have a poor prognosis but both radiation and surgery can be used as salvage therapy. Subtotal resection can result in a stable or improved status in as many as 50% of patients who relapse after primary therapy. Radiation therapy may also salvage some patients with local recurrence. One series reported a 2-year actuarial local control rate of 33% for patients treated with proton beam irradiation.
引用
收藏
页码:1344 / 1350
页数:7
相关论文
共 85 条
[11]  
BILSKY MH, 2004, NEUROSURGERY, V823, P54
[12]  
BJORNSSON J, 1993, CANCER-AM CANCER SOC, V71, P735, DOI 10.1002/1097-0142(19930201)71:3<735::AID-CNCR2820710314>3.0.CO
[13]  
2-8
[14]   Chordoma of the mobile spine: Fifty years of experience [J].
Boriani, S ;
Bandiera, S ;
Biagini, R ;
Bacchini, P ;
Boriani, L ;
Cappuccio, M ;
Chevalley, F ;
Gasbarrini, A ;
Picci, P ;
Weinstein, JN .
SPINE, 2006, 31 (04) :493-503
[15]   En bloc removal of the lower lumbar vertebral body for chordoma - Report of two cases [J].
Bosma, JJD ;
Pigott, TJD ;
Pennie, BH ;
Jaffray, DC .
JOURNAL OF NEUROSURGERY, 2001, 94 (02) :284-291
[16]   CYTOGENETIC AND MOLECULAR CYTOGENETIC ANALYSIS OF SACRAL CHORDOMA [J].
BRIDGE, JA ;
PICKERING, D ;
NEFF, JR .
CANCER GENETICS AND CYTOGENETICS, 1994, 75 (01) :23-25
[17]   Activating mutations in c-KIT and PDGFRα are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes [J].
Burger, H ;
den Bakker, MA ;
Kros, JM ;
van Tol, H ;
de Bruin, AM ;
Oosterhuis, W ;
van den Ingh, HFGM ;
van der Harst, E ;
de Schipper, HP ;
Wiemer, EAC ;
Nooter, K .
CANCER BIOLOGY & THERAPY, 2005, 4 (11) :1270-1274
[18]   Cytogenetic, telomere, and telomerase studies in five surgically managed lumbosacral chordomas [J].
Butler, MG ;
Dahir, GA ;
Hedges, LK ;
Juliao, SE ;
Sciadini, MF ;
Schwartz, HS .
CANCER GENETICS AND CYTOGENETICS, 1995, 85 (01) :51-57
[19]   Chromosome telomere integrity of human solid neoplasms [J].
Butler, MG ;
Sciadini, M ;
Hedges, LK ;
Schwartz, HS .
CANCER GENETICS AND CYTOGENETICS, 1996, 86 (01) :50-53
[20]   Chordoma [J].
Casali, Paolo G. ;
Stacchiotti, Silvia ;
Sangalli, Claudia ;
Olmi, Patrizia ;
Gronchi, Alessandro .
CURRENT OPINION IN ONCOLOGY, 2007, 19 (04) :367-370